Per management, its candidate in phase 2, called MariTide, is going swimmingly, and planning for a phase 3 trial is already ...

Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...

On Tuesday, a tiny shred of data on Amgen’s lead obesity candidate — not yet verified — erased $12 billion in market value.

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply ...

As an aside, in the tech space, see What’s Happening With Snap Stock? Although the recent Amgen update didn’t bode well with ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...

Analysts chewed over early data showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone mineral ...

The tab contains data on bone density changes in patients who received Amgen’s obesity prospect MariTide in a phase 1 trial.

Amgen (AMGN) issued the following statement on the MariTide Phase 1 data. “As previously stated, Amgen does not see an association ...